It's hard to forget how euphoric investors were back in 2021 and 2022.

We're reaching those levels again today.

Back then, stocks were all anyone could talk about...

Folks were stuck at home because of COVID-19 and investing their stimulus checks in the market. Meme stocks were blowing up message boards. And commission-free trading was more accessible than ever.

In 2021, retail investors (i.e., nonprofessional) accounted for about 20% of all U.S. stock-trading volume. This was a big change, as institutions had historically dominated trading. That percentage remained elevated in 2022, at nearly 21% of trading volume.

Of course, most retail investors chase whatever's hot. At the time, that was software stocks and companies benefiting from the work-from-home boom.

Then the market crashed, and retail investors got burned.

By the fall of 2022, the tech-heavy Nasdaq Composite Index had fallen from its peak by about 36%. Many individual work-from-home stocks did much worse. Zoom Communications (ZM), for example, plunged more than 80% from its high.

As you can see below, retail-trading activity had fallen back to around 18% by the time the bear market was over...

You'll also notice in the chart that retail investors now account for more than 20% of all U.S. trading volume – just like in 2022.

These folks are once again a major force behind the market's advance. Their enthusiasm and risk appetite is high.

And just like last time, they're pouring money into the hottest parts of the market. That's tech and AI... even though these companies are already richly valued. In fact, the S&P 500 Index's tech sector trades for about 11 times sales versus the index's average valuation of less than 4 times sales.

We can tell investors are piling into tech based on the amount of cash flowing into tech funds each week. This past week, tech funds saw record inflows. Take a look...

Tech is everything today. As I wrote last week, tech makes up a massive portion of the S&P 500.

It's even dominating value funds.

The iShares Russell 1000 Value Fund (IWD) now contains a higher percentage of "growth" stocks than traditional "value" stocks...

Historically, a value fund behaved exactly as you would expect... Value stocks typically accounted for a majority of the fund, at 50% to 65% of its total weight. And growth stocks made up little to none of the fund, usually sitting in the single digits.

Investors often assume that a value fund buys companies with low price-to-earnings ratios, good dividend yields, and steady, boring business models. However, indexes like the Russell 1000 operate on mathematical rules, not business-model philosophies.

When massive tech and growth giants experience a temporary pullback in valuation, a slowdown in earnings growth, or simply become cheaper relative to the broader market, the index's algorithmic rules automatically reclassify portions of them as value.

Because these tech giants are so large, even a small allocation to them can outweigh investments in traditional value sectors like financials, energy, and utilities.

(The previous chart is a reminder that Wall Street's quantitative definition of value is often completely detached from what a regular investor considers a value stock.)

I'll say this again... It's starting to feel a bit like 2021 and 2022.

I wouldn't be surprised if tech experiences a major pullback in the coming months. Things are simply getting too hot in the sector.

A prime example is Elon Musk's SpaceX (SPCX), which recently completed the biggest initial public offering ("IPO") in history. The company has a nearly $2.7 trillion valuation... even though it's currently unprofitable and lost about $5 billion last year.

My friend and colleague Whitney Tilson says the SpaceX IPO could create a disaster for older Americans...

Even if you never buy a share directly, a little-known change to stock market index rules could mean millions of investors end up owning SpaceX without realizing it.

As Whitney notes, "The indexes are being completely corrupted in a way they never have been before."

If you have money in a 401(k), that's bad news for you. And it means your wealth is at risk.

To learn more from Whitney about these index rule changes and how you can protect your portfolio today, click here.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
June 17, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top